Literature DB >> 8020534

Cimetidine and omeprazole do not affect cyclosporine disposition by the rat liver.

S Bar-Meir1, E Bardan, I Ronen, Z Krepel, M Garti.   

Abstract

Cyclosporine has been used with increased frequency, occasionally in conjunction with cimetidine and omeprazole. The present study was undertaken to study a possible interaction between either of the two drugs and cyclosporine in the liver. The isolated perfused rat liver was used with recirculation of perfusate for 150 min. 6 experiments were performed with each of the following: cyclosporine alone, cyclosporine with cimetidine, and cyclosporine with omeprazole. Initial concentrations of cyclosporine, cimetidine and omeprazole were 600 micrograms/ml, 12.5 micrograms/ml, and 4.5 micrograms/ml, respectively. At 1 and 2 h of perfusion 1 micrograms of omeprazole was added to perfusate. Cyclosporine concentration was determined at 30 min intervals. Results at 150 min expressed as percentage of the initial concentration of cyclosporine were 59 +/- 3%, 55 +/- 6%, and 60 +/- 9% for cyclosporine alone, with cimetidine and with omeprazole, respectively. The elimination rate of cyclosporine by the liver did not change during the entire experiment with the addition of cimetidine or omeprazole. Thus, it is concluded that short administration of cimetidine or omeprazole will not affect cyclosporine metabolism by the liver.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8020534     DOI: 10.1007/BF03190185

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  23 in total

1.  Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators.

Authors:  T Andersson; C G Regårdh; M L Dahl-Puustinen; L Bertilsson
Journal:  Ther Drug Monit       Date:  1990-07       Impact factor: 3.681

2.  Interactions of imidazole antifungal agents with purified cytochrome P-450 proteins.

Authors:  A D Rodrigues; G G Gibson; C Ioannides; D V Parke
Journal:  Biochem Pharmacol       Date:  1987-12-15       Impact factor: 5.858

3.  Ranitidine, cimetidine, and the cyclosporine-treated recipient.

Authors:  M V Jarowenko; C T Van Buren; W G Kramer; M I Lorber; S M Flechner; B D Kahan
Journal:  Transplantation       Date:  1986-09       Impact factor: 4.939

Review 4.  Drug interactions with cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

5.  Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450.

Authors:  D Diaz; I Fabre; M Daujat; B Saint Aubert; P Bories; H Michel; P Maurel
Journal:  Gastroenterology       Date:  1990-09       Impact factor: 22.682

6.  Ketoconazole: a potent inhibitor of cytochrome P-450-dependent drug metabolism in rat liver.

Authors:  J J Sheets; J I Mason
Journal:  Drug Metab Dispos       Date:  1984 Sep-Oct       Impact factor: 3.922

7.  The interaction of omeprazole with rat liver cytochrome P450-mediated monooxygenase reactions in vitro and in vivo.

Authors:  R J Chenery; A Ayrton; H G Oldham; S J Norman; P Standring
Journal:  Biochem Pharmacol       Date:  1988-04-01       Impact factor: 5.858

8.  The effect of PGE2 on hepatic blood flow and bile indocyanin green in the rat.

Authors:  R Bruck; Z Krepel; E Melzer; S Bar-Meir
Journal:  Prostaglandins       Date:  1989-05

9.  Effects of H2-receptor antagonists on renal function in cyclosporine-treated renal transplant patients.

Authors:  J Pachon; M I Lorber; M J Bia
Journal:  Transplantation       Date:  1989-02       Impact factor: 4.939

10.  Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA.

Authors:  M R Lucey; J C Kolars; R M Merion; D A Campbell; M Aldrich; P B Watkins
Journal:  Lancet       Date:  1990-01-06       Impact factor: 79.321

View more
  1 in total

Review 1.  Oral cyclosporine treatment in dogs: a review of the literature.

Authors:  T M Archer; D M Boothe; V C Langston; C L Fellman; K V Lunsford; A J Mackin
Journal:  J Vet Intern Med       Date:  2013-12-16       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.